Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

Inclusion Criteria: * Patients must have platinum-sensitive or platinum-resistant recurrent or persistent or refractory ovarian, fallopian tube, or primary peritoneal carcinoma AND have one or more of the following characteristics documented on a validated platform (documented genetic test report is required). Historic report is permitted. * A germline BRCA1 or BRCA2 deleterious alteration. * A somatic mutation in BRCA1 or BRCA2 detected in a tumor sample or on circulating tumor DNA * Carry a known or likely loss of function alteration in one or more of the homologous recombination or mismatch repair pathways genes * Demonstrate a genomic phenotype of HR deficiency as measured by a LOH-high score. * Recurrent ovarian cancer is defined as recurrence of disease in a patient who achieved initial complete response to primary therapy * Persistent ovarian cancer is defined as having residual disease in the form of elevated tumor markers or microscopic or clinically evident disease in a patient who has completed and apparently responded to initial chemotherapy * Refractory ovarian cancer is defined as patients who have failed to achieve at least a partial response to therapy including patients with either stable disease or disease progression during primary therapy * Platinum-sensitive is defined as achievement of documented response to initial platinum-based treatment and has been off treatment for an extended period of time (more than 6 months) * Platinum-resistant is …